PMID- 14515729
OWN - NLM
STAT- MEDLINE
DCOM- 20031125
LR  - 20110727
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 61
IP  - 9
DP  - 2003 Sep
TI  - [Adult T cell leukemia/lymphoma (ATL)].
PG  - 1592-5
AB  - Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated 
      with human T-lymphotropic virus type I(HTLV-I). The median survival time of 
      acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to 
      recent reports, nearly half of the ATL patients who received allogeneic 
      hematopoietic stem cell transplantation could survive without disease for over 3 
      years. However, the population of patients who are eligible for conventional 
      transplantation is extremely limited. Therefore, a reduced-intensity allogeneic 
      stem cell transplantation(RIST) is applied to ATL patients and a multi-center 
      phase I clinical trial is now underway. In our institute, 5 patients, who 
      received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is 
      considered very promising.
FAU - Tanosaki, Ryuji
AU  - Tanosaki R
AD  - Division of Laboratory Medicine, National Cancer Center Hospital.
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
MH  - Animals
MH  - Clinical Trials, Phase I as Topic
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia-Lymphoma, Adult T-Cell/*therapy
MH  - Male
MH  - Middle Aged
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
RF  - 6
EDAT- 2003/10/01 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/01 05:00
PHST- 2003/10/01 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/01 05:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2003 Sep;61(9):1592-5.